| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Abdulmuttalip Simsek, Sinan Levent Kirecci, Onur Kucuktopcu, Faruk Ozgor, Mehmet Fatih Akbulut, Omer Sarilar, Unsal Ozkuvanci, Zafer Gokhan Gurbu. Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation. Asian journal of andrology. vol 16. issue 5. 2015-06-30. PMID:24830690. |
comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation. |
2015-06-30 |
2023-08-13 |
Not clear |
| Seung Ho Lee, Min Ji Sung, Hyang Mi Lee, Daehyun Chu, Sang June Hahn, Su-Hyun Jo, Han Choe, Bok Hee Cho. Blockade of HERG human K+ channels by the antidepressant drug paroxetine. Biological & pharmaceutical bulletin. vol 37. issue 9. 2015-05-22. PMID:25177033. |
the effects of paroxetine, a selective serotonin reuptake inhibitor, on human ether-a-go-go-related gene (herg) channels were investigated using the whole-cell patch-clamp technique. |
2015-05-22 |
2023-08-13 |
human |
| Jun Tang, Jing Dong, Li Yang, Lingqi Gao, Jijian Zhen. Paroxetine alleviates rat limb post-ischemia induced allodynia through GRK2 upregulation in superior cervical ganglia. International journal of clinical and experimental medicine. vol 8. issue 2. 2015-05-01. PMID:25932137. |
here, we investigated the effects of paroxetine (a selective serotonin reuptake inhibitor and grk2 inhibitor) on grk2 expression in superior cervical ganglion (scg) in a rat model of complex regional pain syndrome type i (crps-i). |
2015-05-01 |
2023-08-13 |
rat |
| Clare M Mathes, Alan C Specto. Systemic modulation of serotonergic synapses via reuptake blockade or 5HT1A receptor antagonism does not alter perithreshold taste sensitivity in rats. Chemical senses. vol 39. issue 7. 2015-04-16. PMID:25056731. |
systemic blockade of serotonin (5ht) reuptake with paroxetine has been shown to increase sensitivity to sucrose and quinine in humans. |
2015-04-16 |
2023-08-13 |
rat |
| Carlotta Belaise, Alessia Gatti, Virginie-Anne Chouinard, Guy Chouinar. Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychotherapy and psychosomatics. vol 83. issue 4. 2015-03-31. PMID:24968739. |
persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. |
2015-03-31 |
2023-08-13 |
Not clear |
| Nitasha Agrawal, Josep Esteve-Romero, Devasish Bose, Neeti Prakesh Dubey, Juan Peris-Vicente, Samuel Carda-Broc. Determination of selective serotonin reuptake inhibitors in plasma and urine by micellar liquid chromatography coupled to fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 965. 2015-03-30. PMID:25023211. |
citalopram, paroxetine and fluoxetine are selective serotonin reuptake inhibitor (ssris) currently used in the treatment of psychiatric disorders. |
2015-03-30 |
2023-08-13 |
Not clear |
| Rui Tao, Mary Rudacille, Gongliang Zhang, Zhiyuan M. Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 8. 2015-02-12. PMID:24577320. |
syndrome intensity was estimated by measuring 5-ht efflux, neuromuscular activity, and body-core temperature in response to challenge injection of clorgyline combined with the ssri paroxetine. |
2015-02-12 |
2023-08-12 |
rat |
| Tamaki Ishima, Yuko Fujita, Kenji Hashimot. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European journal of pharmacology. vol 727. 2015-01-29. PMID:24508523. |
first, we examined the effects of selective serotonin reuptake inhibitors (ssris) (fluvoxamine, paroxetine, sertraline, citalopram and escitalopram), serotonin and noradrenaline reuptake inhibitors (snris) (duloxetine, venlafaxine, milnacipran), and mirtazapine, a noradrenaline and specific serotonergic antidepressant (nassa), on [(3)h](+)-pentazocine binding to rat brain membranes. |
2015-01-29 |
2023-08-12 |
rat |
| Kai Wang, Siyuan Sun, Liping Li, Meijuan Tu, Huidi Jian. Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action. Progress in neuro-psychopharmacology & biological psychiatry. vol 53. 2015-01-22. PMID:24657329. |
the tested antidepressant agents included selective serotonin reuptake inhibitors (ssris, fluoxetine, sertraline and paroxetine), tricyclic antidepressants (tcas, amitriptyline, imipramine, desipramine), monoamine oxidase inhibitor (maoi, moclobemide), serotonin-norepinephrine reuptake inhibitor (snri, venlafaxine) and reported antidepressant alkaloid piperine. |
2015-01-22 |
2023-08-12 |
Not clear |
| Prannay Gulati, B S Chavan, Subhash Da. Paroxetine-induced galactorrhea. Indian journal of psychiatry. vol 56. issue 4. 2015-01-08. PMID:25568484. |
drug-induced galactorrhea has been reported with agents such as antidopaminergic antiemetics, antipsychotics, etc., with few case reports of galactorrhea with selective serotonin reuptake inhibitors, including paroxetine, being reported in last few decades. |
2015-01-08 |
2023-08-13 |
Not clear |
| Fuchun Jing, Jun Zhan. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Digestive diseases and sciences. vol 59. issue 11. 2015-01-05. PMID:24916714. |
an increasing body of research has found fgids to be closely associated with 5-ht, and drugs such as citalopram, paroxetine, venlafaxine, alosetron, tegaserod, prucalopride and mosapride have all been developed or discovered from the perspective of the metabolic kinetics of 5-ht. |
2015-01-05 |
2023-08-13 |
Not clear |
| Maria Nardell, Rajesh R Tamp. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. American journal of Alzheimer's disease and other dementias. vol 29. issue 2. 2014-12-22. PMID:24164931. |
of these, 2 trials used the selective serotonin reuptake inhibitor (ssri), paroxetine; 1 trial used trazodone; 2 trials used stimulants (methylphenidate and dextroamphetamine); 1 trial used the acetylcholinesterase inhibitor, galantamine; 2 trials used the n-methyl-d-aspartate antagonist, memantine; and 1 trial used the neuropeptide oxytocin. |
2014-12-22 |
2023-08-12 |
Not clear |
| Liliana J G Silva, André M P T Pereira, Leonor M Meisel, Celeste M Lino, Angelina Pen. A one-year follow-up analysis of antidepressants in Portuguese wastewaters: occurrence and fate, seasonal influence, and risk assessment. The Science of the total environment. vol 490. 2014-12-22. PMID:24858225. |
the occurrence, fate, seasonal influence and environmental risk assessment of four selective serotonin re-uptake inhibitors (ssris) antidepressants, citalopram, fluoxetine, paroxetine and sertraline, were studied in 15 different wastewater treatment plants (wwtps) across portugal. |
2014-12-22 |
2023-08-13 |
Not clear |
| Lauren Weber, Holly L Thacke. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Women's health (London, England). vol 10. issue 2. 2014-10-31. PMID:24601805. |
paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. |
2014-10-31 |
2023-08-12 |
Not clear |
| Lauren Weber, Holly L Thacke. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Women's health (London, England). vol 10. issue 2. 2014-10-31. PMID:24601805. |
paroxetine is a selective serotonin reuptake inhibitor, and is thought to help decrease vms by regulating body temperature via neurotransmitters. |
2014-10-31 |
2023-08-12 |
Not clear |
| Joanna Mika, Magdalena Zychowska, Wioletta Makuch, Ewelina Rojewska, Barbara Przewlock. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacological reports : PR. vol 65. issue 6. 2014-10-14. PMID:24553009. |
in this review, we present the available publications on tcas (amitriptyline, doxepin, imipramine, desipramine, nortriptyline), tecas (amoxapine, maprotiline), selective serotonin reuptake inhibitors (ssris) (citalopram, fluoxetine, paroxetine), snris (duloxetine, venlafaxine, milnacipran) and atypical antidepressants (bupropion) for the treatment of neuropathic pain. |
2014-10-14 |
2023-08-12 |
Not clear |
| Akiko Aoki, Shin Ishiguro, Takashi Watanabe, Mikito Ueda, Yuki Hayashi, Kazufumi Akiyama, Kazuko Kato, Yoshimasa Inoue, Shoko Tsuchimine, Norio Yasui-Furukori, Kazutaka Shimod. Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder. Neuropsychiatric disease and treatment. vol 10. 2014-09-26. PMID:25258536. |
the aims of the present study were to analyze the association between discontinuation of paroxetine (pax) and the genetic variants of the polymorphism in the serotonin transporter gene-linked polymorphic region (5-httlpr) in japanese patients with panic disorder (pd) and major depressive disorder (mdd). |
2014-09-26 |
2023-08-13 |
Not clear |
| Rong-Pei Liu, Ming Zou, Jian-Yong Wang, Juan-Juan Zhu, Jun-Mei Lai, Li-Li Zhou, Song-Fang Chen, Xiong Zhang, Jian-Hong Zh. Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling. Journal of neuroinflammation. vol 11. 2014-09-16. PMID:24618100. |
paroxetine, a selective serotonin reuptake inhibitor for counteracting depression, has been recently suggested as having a role in prevention of dopaminergic neuronal degeneration in substantia nigra, a hallmark of parkinson's disease (pd). |
2014-09-16 |
2023-08-12 |
Not clear |
| Jennifer R Fanning, Mitchell E Berman, Casey R Guillot, Angelika Marsic, Michael S McCloske. Serotonin (5-HT) augmentation reduces provoked aggression associated with primary psychopathy traits. Journal of personality disorders. vol 28. issue 3. 2014-09-08. PMID:22984854. |
participants (n = 47) completed a self-report measure of psychopathy and were then administered either 40 mg paroxetine (acutely augmenting 5-ht) or placebo. |
2014-09-08 |
2023-08-12 |
human |
| Melissa M Conti, Corinne Y Ostock, David Lindenbach, Adam A Goldenberg, Elias Kampton, Rich Dell'isola, Aaron C Katzman, Christopher Bisho. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology. vol 77. 2014-08-26. PMID:24067924. |
rats received 3 weeks of daily co-treatment of the selective 5-ht reuptake inhibitors (ssris) citalopram (0, 3, or 5 mg/kg) or paroxetine (0, 0.5, or 1.25 mg/kg) with l-dopa (6 mg/kg) during which aims and motor performance were monitored. |
2014-08-26 |
2023-08-12 |
human |